131 related articles for article (PubMed ID: 21455584)
1. Vav3 oncogene is involved in regulation of secretory phospholipase A2-IIa expression in prostate cancer.
Dong Z; Liu Y; Levin L; Oleksowicz L; Wang J; Lu S
Oncol Rep; 2011 Jun; 25(6):1511-6. PubMed ID: 21455584
[TBL] [Abstract][Full Text] [Related]
2. Secretory phospholipase A2-IIa is involved in prostate cancer progression and may potentially serve as a biomarker for prostate cancer.
Dong Z; Liu Y; Scott KF; Levin L; Gaitonde K; Bracken RB; Burke B; Zhai QJ; Wang J; Oleksowicz L; Lu S
Carcinogenesis; 2010 Nov; 31(11):1948-55. PubMed ID: 20837598
[TBL] [Abstract][Full Text] [Related]
3. Vav3 oncogene is overexpressed and regulates cell growth and androgen receptor activity in human prostate cancer.
Dong Z; Liu Y; Lu S; Wang A; Lee K; Wang LH; Revelo M; Lu S
Mol Endocrinol; 2006 Oct; 20(10):2315-25. PubMed ID: 16762975
[TBL] [Abstract][Full Text] [Related]
4. The Vav3 oncogene enhances the malignant potential of prostate cancer cells under chronic hypoxia.
Hirai K; Nomura T; Yamasaki M; Inoue T; Narimatsu T; Chisato Nakada PD; Yoshiyuki Tsukamoto PD; Matsuura K; Sato F; Moriyama M; Mimata H
Urol Oncol; 2014 Feb; 32(2):101-9. PubMed ID: 23403204
[TBL] [Abstract][Full Text] [Related]
5. Secretory phospholipase A2-IIa is a target gene of the HER/HER2-elicited pathway and a potential plasma biomarker for poor prognosis of prostate cancer.
Oleksowicz L; Liu Y; Bracken RB; Gaitonde K; Burke B; Succop P; Levin L; Dong Z; Lu S
Prostate; 2012 Jul; 72(10):1140-9. PubMed ID: 22127954
[TBL] [Abstract][Full Text] [Related]
6. Constitutive activation of nuclear factor kappaB p50/p65 and Fra-1 and JunD is essential for deregulated interleukin 6 expression in prostate cancer.
Zerbini LF; Wang Y; Cho JY; Libermann TA
Cancer Res; 2003 May; 63(9):2206-15. PubMed ID: 12727841
[TBL] [Abstract][Full Text] [Related]
7. Vav3-rac1 signaling regulates prostate cancer metastasis with elevated Vav3 expression correlating with prostate cancer progression and posttreatment recurrence.
Lin KT; Gong J; Li CF; Jang TH; Chen WL; Chen HJ; Wang LH
Cancer Res; 2012 Jun; 72(12):3000-9. PubMed ID: 22659453
[TBL] [Abstract][Full Text] [Related]
8. The molecular mechanism of Vav3 oncogene on upregulation of androgen receptor activity in prostate cancer cells.
Liu Y; Wu X; Dong Z; Lu S
Int J Oncol; 2010 Mar; 36(3):623-33. PubMed ID: 20126983
[TBL] [Abstract][Full Text] [Related]
9. Secretory phospholipase A2-IIa upregulates HER/HER2-elicited signaling in lung cancer cells.
Dong Z; Meller J; Succop P; Wang J; Wikenheiser-Brokamp K; Starnes S; Lu S
Int J Oncol; 2014 Sep; 45(3):978-84. PubMed ID: 24913497
[TBL] [Abstract][Full Text] [Related]
10. Increased expression and activity of group IIA and X secretory phospholipase A2 in peritumoral versus central colon carcinoma tissue.
Tribler L; Jensen LT; Jørgensen K; Brünner N; Gelb MH; Nielsen HJ; Jensen SS
Anticancer Res; 2007; 27(5A):3179-85. PubMed ID: 17970059
[TBL] [Abstract][Full Text] [Related]
11. Targeted overexpression of vav3 oncogene in prostatic epithelium induces nonbacterial prostatitis and prostate cancer.
Liu Y; Mo JQ; Hu Q; Boivin G; Levin L; Lu S; Yang D; Dong Z; Lu S
Cancer Res; 2008 Aug; 68(15):6396-406. PubMed ID: 18676865
[TBL] [Abstract][Full Text] [Related]
12. HER2 expression and gene amplification in pT2a Gleason score 6 prostate cancer incidentally detected in cystoprostatectomies: comparison with clinically detected androgen-dependent and androgen-independent cancer.
Montironi R; Mazzucchelli R; Barbisan F; Stramazzotti D; Santinelli A; Scarpelli M; Lòpez Beltran A
Hum Pathol; 2006 Sep; 37(9):1137-44. PubMed ID: 16938518
[TBL] [Abstract][Full Text] [Related]
13. Group IIA phospholipase A as a prognostic marker in prostate cancer: relevance to clinicopathological variables and disease-specific mortality.
Mirtti T; Laine VJ; Hiekkanen H; Hurme S; Rowe O; Nevalainen TJ; Kallajoki M; Alanen K
APMIS; 2009 Mar; 117(3):151-61. PubMed ID: 19245588
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical analysis of NF-kappaB signaling proteins IKKepsilon, p50/p105, p52/p100 and RelA in prostate cancers.
Seo SI; Song SY; Kang MR; Kim MS; Oh JE; Kim YR; Lee JY; Yoo NJ; Lee SH
APMIS; 2009 Aug; 117(8):623-8. PubMed ID: 19664134
[TBL] [Abstract][Full Text] [Related]
15. PI3K-Akt signaling is involved in the regulation of p21(WAF/CIP) expression and androgen-independent growth in prostate cancer cells.
Lu S; Ren C; Liu Y; Epner DE
Int J Oncol; 2006 Jan; 28(1):245-51. PubMed ID: 16328002
[TBL] [Abstract][Full Text] [Related]
16. Nipple aspirate fluids from women with breast cancer contain increased levels of group IIa secretory phospholipase A2.
Mannello F; Qin W; Zhu W; Fabbri L; Tonti GA; Sauter ER
Breast Cancer Res Treat; 2008 Sep; 111(2):209-18. PubMed ID: 17932742
[TBL] [Abstract][Full Text] [Related]
17. Role of coordinated molecular alterations in the development of androgen-independent prostate cancer: an in vitro model that corroborates clinical observations.
Shi Y; Chatterjee SJ; Brands FH; Shi SR; Pootrakul L; Taylor CR; Datar R; Cote RJ
BJU Int; 2006 Jan; 97(1):170-8. PubMed ID: 16336351
[TBL] [Abstract][Full Text] [Related]
18. Vav3 oncogene activates estrogen receptor and its overexpression may be involved in human breast cancer.
Lee K; Liu Y; Mo JQ; Zhang J; Dong Z; Lu S
BMC Cancer; 2008 Jun; 8():158. PubMed ID: 18518979
[TBL] [Abstract][Full Text] [Related]
19. Simvastatin inhibits sPLA2 IIa expression in aorta and myocardium.
Wei-hua L; Chang-qing S; Qiang X; Rong W; Kai-min L
Arch Med Res; 2009 Feb; 40(2):67-72. PubMed ID: 19237014
[TBL] [Abstract][Full Text] [Related]
20. Steroid receptor coactivator-3 and activator protein-1 coordinately regulate the transcription of components of the insulin-like growth factor/AKT signaling pathway.
Yan J; Yu CT; Ozen M; Ittmann M; Tsai SY; Tsai MJ
Cancer Res; 2006 Nov; 66(22):11039-46. PubMed ID: 17108143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
